Uncover drug interactions
Drug interactions are a major course of adverse events and compromised therapeutic efficacy. The incidence of drug interactions increases with the number of medications a patient uses, making polypharmacy a notable clinical issue, particularly among the elderly.
Clinically relevant drug interactions frequently lead to adverse reactions and reduced drug efficacy. Potentially significant drug interactions occur in about 42% of the general population who take at least two medications (1). These interactions account for about 12% of adverse drug reactions (2) and may result in hospitalisation (3).
42%
“Potentially significant drug interactions occur in about 42% of the general population who take at least two medications.”
Clinical solution
Inxbase does not only detail the consequences of each interaction but also provides comprehensive information on how to avoid or control the associated clinical risks. The dataset includes analyses of the mechanisms underlying each interaction and offers fully referenced, transparent analyses of the existing scientific data on each interaction.
Key characteristics
of Inxbase
- Recommendations on avoiding, handling and monitoring potential drug interactions
- Descriptions of consequences and outcomes of interactions
- Short descriptions of the mechanism of interactions supported by scientific evidence with references to peer-reviewed literature
- Consideration of active substance formulations and drug administration routes
- Extrapolation of foreseeable clinically significant pharmacokinetic interactions, such as known metabolic pathways
- Inclusion of prescription and over-the-counter drugs as well as clinically relevant drug-herbal and drug-food interactions
Classification methodology
All potential interactions are classified using GRADE (Grading of Recommendations, Assessment, Development and Evaluation) methodology according to clinical significance (A–D), resulting in a traffic light-like system:
| D | Clinically relevant interaction that is best avoided |
| C | Clinically relevant interaction that can be handled by, for example, dose adjustments |
| B | The clinical outcome of the interaction is uncertain and/or may vary |
| A | Minor interaction of no clinical relevance |
The evidence is graded according to the following numbers:
| 0 | Data derived from extrapolation based on studies with similar drugs |
| 1 | Data derived from incomplete case reports and/or in vitro studies |
| 2 | Data derived from well-documented case reports |
| 3 | Data derived from studies among healthy volunteers and/or pilot studies among patients |
| 4 | Data derived from controlled studies in a relevant patient population |
Languages and local drug registries
Medbase content is available in English and more than ten additional languages. To further improve local usability, we accommodate national, local and customer-specific drug product registries, allowing access to information using local drug product names and IDs.
Integration with local electronic health record (EHR) systems is straightforward, enabling smooth and efficient use of regularly updated Medbase drug information across various countries.
Latest information from trusted sources
All information is based on scientific evidence. We refer to published, peer-reviewed research articles from PubMed, a reliable source of biomedical and life sciences literature, as well as regulatory authority approved documents, such as the Summaries of Product Characteristics (SPC) of drugs.
Medbase Knowledgebase is continuously updated to ensure the inclusion of the latest information.
Supporting informed decisions for safe drug use
Enhanced patient safety
Holistic approach to patient’s pharmacotherapy enabling individualised drug treatment.
100% Evidence-based
Fully referenced information with transparency to original sources: documents approved by regulatory authorities and peer-reviewed literature.
Clinical relevance
We provide comprehensive and concise information for safe use of drugs, accessible from one single source.
Digitalised doctor consultation
Designed to support busy clinical practice for safe use of drugs. All information is created and validated by physicians specialised in clinical pharmacology.
Newsroom
Discover our latest updates & customer references
Genetic variability affects outcomes of drug therapy
- Interview
- PROF. MIKKO NIEMI
“Our product development is foresighted”
- Our People
- CPO MARKUS JANSÉN
Vaaka Partners to invest in Medbase
- Interview
- Holm J, Eiermann B, Eliasson E, Mannheimer B. A limited number of prescribed drugs account for the great majority of drug-drug interactions. Eur J Clin Pharmacol. 2014 Nov;70(11):1375-83.
- Odar-Cederlöf I, Oskarsson P, Ohlén G, Tesfa Y, Bergendal A, Helldén A, Bergman U. Adverse drug effect as cause of hospital admission. Common drugs are the major part according to the cross-sectional study. Lakartidningen. 2008 Mar 18-Apr 1;105(12-13):890-3.
- Dechanont S, Maphanta S, Butthum B, Kongkaew C. Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2014 May;23(5):489-97.